CA2959688C - Quinolone compounds and their use to treat diseases related to hypoxia inducible factor and/or erythropoietin - Google Patents
Quinolone compounds and their use to treat diseases related to hypoxia inducible factor and/or erythropoietin Download PDFInfo
- Publication number
- CA2959688C CA2959688C CA2959688A CA2959688A CA2959688C CA 2959688 C CA2959688 C CA 2959688C CA 2959688 A CA2959688 A CA 2959688A CA 2959688 A CA2959688 A CA 2959688A CA 2959688 C CA2959688 C CA 2959688C
- Authority
- CA
- Canada
- Prior art keywords
- mmol
- independently
- methyl
- hydroxy
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410442574 | 2014-09-02 | ||
| CN201410442574.4 | 2014-09-02 | ||
| PCT/CN2015/088799 WO2016034108A1 (zh) | 2014-09-02 | 2015-09-01 | 喹啉酮类化合物及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2959688A1 CA2959688A1 (en) | 2016-03-10 |
| CA2959688C true CA2959688C (en) | 2024-02-27 |
Family
ID=55417512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2959688A Active CA2959688C (en) | 2014-09-02 | 2015-09-01 | Quinolone compounds and their use to treat diseases related to hypoxia inducible factor and/or erythropoietin |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10065928B2 (enExample) |
| EP (1) | EP3190104B1 (enExample) |
| JP (1) | JP6506390B2 (enExample) |
| CN (1) | CN105384687B (enExample) |
| AU (1) | AU2015311333B2 (enExample) |
| CA (1) | CA2959688C (enExample) |
| ES (1) | ES2898476T3 (enExample) |
| WO (1) | WO2016034108A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106146414A (zh) * | 2016-07-07 | 2016-11-23 | 浙江大学 | 喹唑啉二酮类衍生物及其制备方法和用途 |
| CN108069952B (zh) * | 2016-11-08 | 2022-09-27 | 广东东阳光药业有限公司 | 喹啉酮类化合物及其在药物中应用 |
| CN108069957B (zh) * | 2016-11-09 | 2022-11-04 | 广东东阳光药业有限公司 | 脯氨酰羟化酶抑制剂及其用途 |
| CN108285460A (zh) * | 2017-01-09 | 2018-07-17 | 南京圣和药业股份有限公司 | 一种egfr激酶抑制剂的药用盐及其制备方法与用途 |
| JP6999469B2 (ja) * | 2018-03-28 | 2022-01-18 | 東京応化工業株式会社 | 水素バリア剤、水素バリア膜形成用組成物、水素バリア膜、水素バリア膜の製造方法、及び電子素子 |
| CN111269176A (zh) * | 2019-11-28 | 2020-06-12 | 南北兄弟药业投资有限公司 | 喹啉酮类化合物的晶型 |
| CN111269177B (zh) * | 2019-11-28 | 2023-05-09 | 广东东阳光药业有限公司 | 喹啉酮类化合物的晶型 |
| ES3061349T3 (en) | 2019-11-28 | 2026-04-01 | Sunshine Lake Pharma Co Ltd | Crystal form of 2-(4-hydroxy-1-methyl-2-oxo-7-phenoxy-1,2-dihydroquinoline-3-carboxamido)acetic acid |
| CN111269178A (zh) * | 2019-11-28 | 2020-06-12 | 南北兄弟药业投资有限公司 | 喹啉酮类化合物的晶型 |
| WO2022184159A1 (zh) * | 2021-03-05 | 2022-09-09 | 广东东阳光药业有限公司 | 喹啉酮类化合物的晶型及其用途 |
| CN115010664A (zh) * | 2021-03-05 | 2022-09-06 | 广东东阳光药业有限公司 | 喹啉酮类化合物的晶型及其用途 |
| CN115010663A (zh) * | 2021-03-05 | 2022-09-06 | 广东东阳光药业有限公司 | 喹啉酮类化合物的晶型及其用途 |
| CN114989085B (zh) * | 2022-05-23 | 2023-11-24 | 安徽医科大学 | 一种芳基内酰胺环类化合物、药物组合物及其应用 |
| CN117159549B (zh) * | 2023-10-11 | 2025-02-14 | 中国药科大学 | 一种酯类化合物的应用 |
| CN121405623A (zh) * | 2024-07-24 | 2026-01-27 | 合肥医工医药股份有限公司 | 喹啉衍生物及其制备方法和用途 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100932169B1 (ko) * | 2003-06-06 | 2009-12-16 | 피브로겐, 인크. | 질소-함유 헤테로아릴 화합물 및 내인성 적혈구생성소의증가에서의 그들의 사용 |
| JPWO2006088246A1 (ja) * | 2005-02-18 | 2008-07-10 | 武田薬品工業株式会社 | Ｇｐｒ３４受容体機能調節剤 |
| CN101166745A (zh) | 2005-03-02 | 2008-04-23 | 菲布罗根有限公司 | 噻吩并吡啶化合物和其使用方法 |
| DE102005019712A1 (de) | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
| WO2007038571A2 (en) * | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
| AU2006326662B2 (en) * | 2005-12-09 | 2011-07-28 | Amgen Inc. | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof |
| WO2007090068A2 (en) | 2006-01-27 | 2007-08-09 | Fibrogen, Inc. | Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (hif) |
| AR059733A1 (es) | 2006-03-07 | 2008-04-23 | Smithkline Beecham Corp | Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion |
| EP2016078B1 (en) | 2006-04-04 | 2016-06-15 | Fibrogen, Inc. | Pyrrolo- and thiazolo-pyridine compounds as hif modulators |
| WO2007136990A2 (en) | 2006-05-16 | 2007-11-29 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| JO2934B1 (en) | 2006-06-23 | 2015-09-15 | سميث كلاين بيتشام كوربوريشن | Prolyl hydroxylase inhibitors |
| NZ601730A (en) | 2006-06-26 | 2014-04-30 | Akebia Therapeutics Inc | Prolyl hydroxylase inhibitors and methods of use |
| DE102006050516A1 (de) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dihydropyrazolone und ihre Verwendung |
| EP2111399A2 (en) | 2006-12-18 | 2009-10-28 | Amgen Inc. | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
| ES2393326T3 (es) | 2006-12-18 | 2012-12-20 | Amgen, Inc | Compuestos basados en azaquinolona que presentan actividad inhibidora de prolil hidroxilasas, composiciones y usos de los mismos |
| TW200845994A (en) | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: prolyl hydroxylase inhibitors |
| TW200845991A (en) | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: hydroxylase inhibitors |
| AU2008241503A1 (en) * | 2007-04-18 | 2008-10-30 | Merck Sharp & Dohme Corp. | Novel 1,8-naphthyridine compounds |
| ES2446418T3 (es) | 2007-04-18 | 2014-03-07 | Amgen, Inc | Derivados de indanona que inhiben la prolil hidroxilasa |
| EP2142509B1 (en) | 2007-04-18 | 2013-12-04 | Amgen, Inc | Quinolones and azaquinolones that inhibit prolyl hydroxylase |
| US8030346B2 (en) | 2007-05-04 | 2011-10-04 | Amgen Inc. | Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity |
| CA2696725A1 (en) | 2007-08-10 | 2009-03-26 | Crystalgenomics, Inc. | Pyridine derivatives and methods of use thereof |
| WO2009039321A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009039323A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009039322A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009049112A1 (en) | 2007-10-10 | 2009-04-16 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009073497A2 (en) | 2007-11-30 | 2009-06-11 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| US20100305154A1 (en) | 2007-11-30 | 2010-12-02 | Glaxosmithkline Llc | Prolyl Hydroxylase Inhibitors |
| US8269008B2 (en) | 2007-12-03 | 2012-09-18 | Fibrogen, Inc. | Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions |
| EP2240178A4 (en) | 2007-12-19 | 2011-10-26 | Glaxosmithkline Llc | PROLYLHYDROXYLASEHEMMER |
| EP2252619B1 (en) | 2008-01-11 | 2013-10-09 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity |
| US8324405B2 (en) | 2008-02-05 | 2012-12-04 | Fibrogen, Inc. | Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors |
| CN101951775A (zh) | 2008-02-25 | 2011-01-19 | 默沙东公司 | 四氢噻吩并吡啶 |
| CA2716798A1 (en) | 2008-02-25 | 2009-09-03 | Merck Sharp & Dohme Corp. | Tetrahydrofuropyridones |
| CA2714111A1 (en) | 2008-02-25 | 2009-09-03 | Merck Sharp & Dohme Corp. | Tetrahydro-1h-pyrrolo fused pyridones |
| US8759345B2 (en) | 2008-04-28 | 2014-06-24 | Janssen Pharmaceutica Nv | Benzoimidazoles as prolyl hydroxylase inhibitors |
| WO2009134850A1 (en) | 2008-04-30 | 2009-11-05 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009134847A1 (en) | 2008-04-30 | 2009-11-05 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| JP2011525924A (ja) | 2008-06-25 | 2011-09-29 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | プロリルヒドロキシラーゼ阻害剤 |
| US8217043B2 (en) | 2008-08-20 | 2012-07-10 | Fibrogen, Inc. | Compounds and methods for their use |
| WO2010022307A2 (en) | 2008-08-21 | 2010-02-25 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| JP2012500850A (ja) | 2008-08-25 | 2012-01-12 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | プロリルヒドロキシラーゼ阻害剤 |
| CN102272117B (zh) | 2008-11-14 | 2015-06-17 | 菲布罗根有限公司 | 作为hif羟化酶抑制剂的苯并噻喃衍生物 |
| WO2010093727A1 (en) | 2009-02-10 | 2010-08-19 | Janssen Pharmaceutica Nv | Quinazolinones as prolyl hydroxylase inhibitors |
| CN102164905B (zh) | 2009-07-15 | 2014-04-30 | 北京贝美拓新药研发有限公司 | 作为体内缺氧模拟剂的化合物，组合物，及其应用 |
| PT2455381E (pt) | 2009-07-17 | 2014-06-24 | Japan Tobacco Inc | Composto de triazolopiridina e sua acção como inibidor da prolil-hidroxilase e indutor da produção de eritropoietina |
| WO2011048611A1 (en) | 2009-10-07 | 2011-04-28 | Torrent Pharmaceuticals Limited | Novel fused pyridazine derivatives |
| TWI500623B (zh) | 2009-10-13 | 2015-09-21 | Torrent Pharmaceuticals Ltd | 新穎稠合噻唑及噁唑嘧啶酮 |
| WO2011056725A1 (en) | 2009-11-05 | 2011-05-12 | Crystalgenomics, Inc. | Pyridine derivatives and methods of use thereof |
| US8541430B2 (en) | 2009-11-27 | 2013-09-24 | Torrent Pharmaceuticals Limited | Fused thiazolo and oxazolo pyrimidinones |
| US8796263B2 (en) | 2010-08-13 | 2014-08-05 | Janssen Pharmaceutica Nv | 4-aminoquinazolin-2-yl-1-pyrrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors |
| CN103608346B (zh) | 2011-02-02 | 2016-06-15 | 菲布罗根有限公司 | 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物 |
| NO2686520T3 (enExample) | 2011-06-06 | 2018-03-17 | ||
| EP3251671A1 (en) | 2011-06-06 | 2017-12-06 | Akebia Therapeutics Inc. | Compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer |
| JP2014523917A (ja) | 2011-07-29 | 2014-09-18 | ベイジン ベータ ファーマシューティカルズ カンパニー， リミテッド | 低酸素模倣剤としての化合物の安定な多形体、およびその使用 |
| SG11201405574UA (en) | 2012-03-09 | 2014-10-30 | Fibrogen Inc | 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors |
| US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| US9340511B2 (en) | 2012-07-16 | 2016-05-17 | Fibrogen, Inc. | Process for making isoquinoline compounds |
| AU2013297601B2 (en) | 2012-07-30 | 2017-02-16 | Taisho Pharmaceutical Co., Ltd. | Partially saturated nitrogen-containing heterocyclic compound |
| US20150239889A1 (en) | 2012-08-23 | 2015-08-27 | Mitsubishi Tanabe Pharma Corporation | Pyrazolopyrimidine compound |
| NZ708605A (en) * | 2012-12-24 | 2016-07-29 | Cadila Healthcare Ltd | Novel quinolone derivatives |
| WO2014116849A1 (en) | 2013-01-24 | 2014-07-31 | Fibrogen, Inc. | Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid |
-
2015
- 2015-09-01 WO PCT/CN2015/088799 patent/WO2016034108A1/zh not_active Ceased
- 2015-09-01 EP EP15837609.5A patent/EP3190104B1/en active Active
- 2015-09-01 AU AU2015311333A patent/AU2015311333B2/en active Active
- 2015-09-01 CA CA2959688A patent/CA2959688C/en active Active
- 2015-09-01 CN CN201510557206.9A patent/CN105384687B/zh active Active
- 2015-09-01 JP JP2017512046A patent/JP6506390B2/ja active Active
- 2015-09-01 ES ES15837609T patent/ES2898476T3/es active Active
- 2015-09-01 US US15/502,499 patent/US10065928B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN105384687B (zh) | 2018-05-01 |
| AU2015311333B2 (en) | 2017-11-16 |
| CA2959688A1 (en) | 2016-03-10 |
| AU2015311333A1 (en) | 2017-02-16 |
| EP3190104B1 (en) | 2021-10-27 |
| JP6506390B2 (ja) | 2019-04-24 |
| US20170247332A1 (en) | 2017-08-31 |
| EP3190104A4 (en) | 2018-04-11 |
| EP3190104A1 (en) | 2017-07-12 |
| ES2898476T3 (es) | 2022-03-07 |
| US10065928B2 (en) | 2018-09-04 |
| CN105384687A (zh) | 2016-03-09 |
| WO2016034108A1 (zh) | 2016-03-10 |
| JP2017525737A (ja) | 2017-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2015311333B2 (en) | Quinolinone compound and use thereof | |
| WO2023280136A1 (zh) | 氘甲基取代吡嗪并吡嗪并喹啉酮类衍生物、其制备方法及其在医药上的应用 | |
| TWI698435B (zh) | 作為吲哚胺２,３-二加氧酶和/或色氨酸２,３-二加氧酶抑制劑之新穎之５或８-取代之咪唑並［１，５－ａ］吡啶 | |
| EP2875001B1 (en) | Nitrogenous heterocyclic derivatives and their application in drugs | |
| CN115611898A (zh) | 四环类衍生物、其制备方法及其在医药上的应用 | |
| CA3155924A1 (en) | Pyridone compounds and methods of use in the modulation of a protein kinase | |
| CN111315747A (zh) | 二氢吡唑酮并嘧啶类化合物及其制备方法和用途 | |
| CN112851647B (zh) | 布雷菲德菌素a衍生物及其制备方法和用途 | |
| CN103664899A (zh) | 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用 | |
| WO2024088351A1 (en) | Compounds and uses thereof | |
| CN110041253A (zh) | 吡啶类n-氧化衍生物及其制备方法和应用 | |
| CN108069952B (zh) | 喹啉酮类化合物及其在药物中应用 | |
| CN119947717A (zh) | 尿石素衍生物的治疗用途 | |
| WO2018137655A1 (zh) | 吡咯并吡啶类n-氧化衍生物及其制备方法和应用 | |
| CN108069957B (zh) | 脯氨酰羟化酶抑制剂及其用途 | |
| WO2022063333A1 (zh) | 一种嘧啶甲酰胺类化合物及其应用 | |
| WO2022143610A1 (zh) | 新型酰胺吡咯类化合物及其在药物中的应用 | |
| CN104387358B (zh) | 淫羊藿苷类化合物及其应用 | |
| CN119977947A (zh) | Prmt5抑制剂、其药物组合物及其在药物中的应用 | |
| WO2011124093A1 (zh) | 双环喹诺酮类化合物及其制备和应用 | |
| CN104529974B (zh) | 淫羊藿苷类化合物及其应用 | |
| CN104496857B (zh) | 作为神经氨酸酶抑制剂的化合物及其在药物中的应用 | |
| WO2025082531A1 (en) | Compounds and uses thereof | |
| CN118076592A (zh) | Shp2抑制剂、包含其的药物组合物及其用途 | |
| TW202606703A (zh) | 雜環並環類化合物、其藥物組合物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200603 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240826 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240826 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240826 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD Year of fee payment: 10 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250821 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250821 |